Ownership and insider activity for Fortrea Holdings Inc. (FTRE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development.
Price
| Price | $19.97 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $94.6M | $112.0M | $108.6M | $118.5M | $174.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Receivables | $949.8M | $1.05B | $1.01B | $694.0M | $620.0M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.12B | $1.25B | $1.25B | $948.2M | $897.2M |
| Property, Plant & Equipment | $162.6M | $164.9M | $172.6M | $156.3M | $149.5M |
| Goodwill | $2.08B | $2.00B | $1.74B | $1.71B | $960.0M |
| Intangible Assets | $935.5M | $823.3M | $728.1M | $655.7M | $622.0M |
| Total Assets | $4.37B | $4.29B | $4.33B | $3.58B | $2.72B |
| Accounts Payable | $60.5M | $81.5M | $132.9M | $138.2M | $29.7M |
| Short-term Debt | 0 | 0 | $26.1M | $74.8M | $4.8M |
| Total Current Liabilities | $826.7M | $699.0M | $778.4M | $949.5M | $913.3M |
| Long-term Debt | 0 | 0 | $1.57B | $1.05B | $1.05B |
| Total Liabilities | $1.11B | $945.3M | $2.62B | $2.22B | $2.15B |
| Retained Earnings | 0 | 0 | -$68.5M | -$397.0M | -$1.38B |
| Total Equity | $3.26B | $3.34B | $1.71B | $1.36B | $563.5M |
| Total Debt | $77.2M | $63.4M | $1.67B | $1.20B | $1.12B |
| Net Debt | -$17.4M | -$48.6M | $1.56B | $1.08B | $941.4M |
| Working Capital | $290.8M | $547.9M | $472.4M | -$1.3M | -$16.1M |
Financial Health
| Debt / Equity | 2.13 |
| Current Ratio | 0.96 |
Profitability
| Return on Equity | -15.53% |
| Return on Invested Capital | 0.62% |
| Return on Assets | -3.14% |
| Gross Margin | 17.11% |
| Operating Margin | 0.41% |
| Net Margin | -3.18% |
Related companies: ANAB · AVBP · BBOT · EYPT · KURA · MRVI · PHAT
Explore sector: Healthcare · Biotechnology
More sections of FTRE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks